Development
Thermo Fisher Scientific Inc.
TMO
$415.15
$0.610.15%
NYSE
| 12/31/2023 | 09/30/2023 | 07/01/2023 | 04/01/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 42.86B | 43.42B | 43.52B | 43.81B | 44.92B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 42.86B | 43.42B | 43.52B | 43.81B | 44.92B |
| Cost of Revenue | 25.71B | 26.07B | 26.19B | 26.13B | 25.94B |
| Gross Profit | 17.15B | 17.36B | 17.34B | 17.68B | 18.97B |
| SG&A Expenses | 8.35B | 8.49B | 8.66B | 8.77B | 8.93B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.00M | -- | -- | -- | -- |
| Total Operating Expenses | 35.40B | 35.96B | 36.28B | 36.35B | 36.34B |
| Operating Income | 7.46B | 7.46B | 7.24B | 7.46B | 8.58B |
| Income Before Tax | 6.24B | 6.25B | 6.03B | 6.48B | 7.66B |
| Income Tax Expenses | 284.00M | 324.00M | 302.00M | 448.00M | 703.00M |
| Earnings from Continuing Operations | 5.96K | 5.92K | 5.73K | 6.03K | 6.96K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 40.00M | 18.00M | -5.00M | -8.00M | -10.00M |
| Net Income | 6.00B | 5.94B | 5.72B | 6.02B | 6.95B |
| EBIT | 7.46B | 7.46B | 7.24B | 7.46B | 8.58B |
| EBITDA | 10.86B | 10.88B | 10.64B | 10.84B | 11.96B |
| EPS Basic | 15.52 | 15.34 | 14.71 | 15.43 | 17.74 |
| Normalized Basic EPS | 11.23 | 11.16 | 10.63 | 10.95 | 12.76 |
| EPS Diluted | 15.45 | 15.24 | 14.61 | 15.32 | 17.61 |
| Normalized Diluted EPS | 11.18 | 11.10 | 10.57 | 10.89 | 12.68 |
| Average Basic Shares Outstanding | 1.55B | 1.55B | 1.56B | 1.56B | 1.57B |
| Average Diluted Shares Outstanding | 1.55B | 1.56B | 1.56B | 1.57B | 1.58B |
| Dividend Per Share | 1.40 | 1.35 | 1.30 | 1.25 | 1.20 |
| Payout Ratio | 8.72% | 8.48% | 8.51% | 7.79% | 6.55% |